<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">VWF, WM, and angiogenesis: Is there a link?</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868149992&amp;doi=10.1182%2fblood-2012-08-451468&amp;partnerID=40&amp;md5=015b8b19e4740049be1dfb265adf7399</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">120</style></volume><pages><style face="normal" font="default" size="100%">3163 - 3164</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The serum levels of several angiogenic cytokines are increased in patients withWaldenström macroglobulinemia (WM). Angiopoietin-2 is also increased and the balance of angiopoietin-1/angiopoietin-2, which antagonize for the receptor tyrosine kinase Tie-2 is in favor of angiopoietin-2. Lymphoplasmacytic cells may produce VEGF, but they also produce large amounts of CCL-3 which attracts macrophages, and probably mast cells. Mast cells support lymphoplasmacytic cells and may also produce VEGF. VWF is stored in the Weibel-Palade bodies together with several other mediators, including angiopoietin-2. The endothelial cells (ECs) release the content of Weibel-Palade bodies in response to stimuli, such as VEGF and VWF and other molecules (such as angiopoitein-2) are released simultaneously. VWF may also have an inhibitory activity in the constitutive VEGFR-2-dependent pathway(s), which promote EC migration.</style></abstract><issue><style face="normal" font="default" size="100%">16</style></issue><notes><style face="normal" font="default" size="100%">Cited By :2Export Date: 21 February 2017</style></notes></record></records></xml>